Financhill
Back

Regeneron Pharmaceuticals, Inc. 10K Form

Buy
59

REGN
Regeneron Pharmaceuticals, Inc.

Last Price:
$785.06
Seasonality Move:
12.13%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-02 10Q REGN/Regeneron Pharmaceuticals, Inc. Quarterly
2023-11-02 10Q REGN/Regeneron Pharmaceuticals, Inc. Quarterly
2023-08-03 10Q REGN/Regeneron Pharmaceuticals, Inc. Quarterly
2023-05-04 10Q REGN/Regeneron Pharmaceuticals, Inc. Quarterly
2022-11-03 10Q REGN/Regeneron Pharmaceuticals, Inc. Quarterly
2022-08-03 10Q REGN/Regeneron Pharmaceuticals, Inc. Quarterly

Receive REGN News And Ratings

See the #1 stock for the next 7 days that we like better than REGN

REGN Financial Statistics

Sales & Book Value

Annual Sales: $14.2B
Cash Flow: $1.4B
Price / Cash Flow: 22.13
Annual Sales: $294.00
Price / Book: 2.65

Profitability

EPS (TTM): 41.77010
Net Income (TTM): $4.6B
Gross Margin: $11.8B
Return on Equity: 15.37%
Return on Assets: 11.97%

Regeneron Pharmaceuticals, Inc. Earnings Forecast

Key Regeneron Pharmaceuticals, Inc. Financial Ratios

  • The Gross Profit Margin over the past 35 years for REGN is 82.74%.
  • The Selling, General & Administrative Expenses for REGN have been equal to 20.80% of Gross Profit Margin.
  • The Research & Development expenses have been 32.56% of Revenue.
  • The Interest Expense is 1.25% of Operating Income.
  • The Net Earning history of REGN is 31.07% of Total Revenues.
  • Per Share Earnings over the last 35 years have been positive in 19 years.

Regeneron Pharmaceuticals, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: S&P500
Industry: Biotechnology
Sector: Health Care
Current Symbol: REGN
CUSIP: 75886F
Website: regeneron.com

Debt

Debt-to-Equity Ratio: 0.09
Current Ratio: 4.06
Quick Ratio: 3.19

Price-to-Earnings

Trailing P/E Ratio: 20.33
Forward P/E Ratio: 17.65

REGN Technical Analysis vs Fundamental Analysis

Buy
59
Regeneron Pharmaceuticals, Inc. (REGN) is a Buy

Is Regeneron Pharmaceuticals, Inc. a Buy or a Sell?